Cargando…

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis. Upadacitinib is a nonsensitive substrate for metabolism by cytochrome P450 3A enzymes. This open‐label, single‐dose, multicenter study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trueman, Sheryl, Mohamed, Mohamed‐Eslam F., Feng, Tian, Lacerda, Ana Paula, Marbury, Thomas, Othman, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Special Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766976/ https://www.ncbi.nlm.nih.gov/pubmed/30973649 http://dx.doi.org/10.1002/jcph.1414

Ejemplares similares

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
por: He, Ping, et al.
Publicado: (2014)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
por: Dymond, Angela W., et al.
Publicado: (2016)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics
por: Zahir, Hamim, et al.
Publicado: (2022)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Pharmacokinetics of the Dual Melatonin Receptor Agonist Tasimelteon in Subjects With Hepatic or Renal Impairment
por: Torres, Rosarelis, et al.
Publicado: (2015)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment
por: Dudkowski, Caroline, et al.
Publicado: (2017)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2022)

Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
por: Song, Ivy, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
por: Hoover, Randall K., et al.
Publicado: (2018)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
por: Katsube, Takayuki, et al.
Publicado: (2016)

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study
por: Dahlke, Marion, et al.
Publicado: (2015)

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
por: Ponce-Bobadilla, Ana Victoria, et al.
Publicado: (2022)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab
por: Hsu, Cheng‐Pang, et al.
Publicado: (2022)

Acute myocardial injury is common in patients with COVID-19 and impairs their prognosis
por: Wei, Jia-Fu, et al.
Publicado: (2020)

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
por: Ashton, Veronica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n433ipjtdpr0hfp0c7ntcr5ule